The diagnostic value of serum levels of C-reactive protein and procalcitonin in differentiation between active pulmonary TB and CAP

Basem I. El-Shafey\textsuperscript{a}, Hoda M. Bahr\textsuperscript{a}, Salwa A. Ganna\textsuperscript{a}, Mohmad S. Attia\textsuperscript{b}, Mamdouh M. El Rakhawy\textsuperscript{c}

\textbf{Introduction}  
C-reactive protein (CRP) and procalcitonin (PCT) levels are elevated in patients with community-acquired pneumonia (CAP), but PCT does not increase in patients with pulmonary tuberculosis (TB).

\textbf{Aim}  
To evaluate the diagnostic value of serum levels of CRP and PCT in differentiating between active pulmonary TB and CAP.

\textbf{Participants and methods}  
The present study was carried out on 90 individuals divided into the following groups: group I included 10 control participants, group II included 40 patients with active pulmonary TB, and group III included 40 patients with CAP. Serum levels of CRP and PCT were measured.

\textbf{Results}  
CRP was significantly increased in group III compared with groups I and II. PCT was significantly increased in group III compared with groups I and II; also, there was a significant increase in group II compared with group I. The cut-off value of CRP between group II and group III was more than 24 (mg/dl), with a sensitivity of 100%, a specificity of 70%, and that of PCT was more than 530 (pg/ml), with a sensitivity of 67% and a specificity of 97.5%.

\textbf{Conclusion}  
Measurements of CRP and PCT were complementary to each other to differentiate between pulmonary TB and CAP.

\textbf{Keywords:}  
community-acquired pneumonia, C-reactive protein, procalcitonin, tuberculosis

\textbf{Departments of}  
\textsuperscript{a}Chest, \textsuperscript{b}Clinical Pathology, Tanta University, Tanta, \textsuperscript{c}Abbassia Chest Hospital Ministry of Health, Cairo, Egypt

Correspondence to Basem I. El-Shafey, MD, Department of Chest, Tanta University, Elgeish street, Tanta 31515, Egypt
Tel: +20 122 379 8033; e-mail: basemshafeley@yahoo.com

Received 23 February 2015 Accepted 16 March 2015
therapy in patients with CAP by differentiating between classic bacterial and atypical or viral etiology.

This work aims to evaluate the diagnostic value of serum levels of CRP and PCT in differentiating between active pulmonary TB and CAP.

Participants and methods
The present study was carried out on 90 participants; they were recruited from the chest department, Tanta University Hospital, and Abbassia chest hospital during the period from April 2012 till April 2013 and divided into three groups. Group I included 10 apparently healthy normal nonsmoker volunteers, six men and four women, mean age 37.1 ± 10.816 years. Group II included 40 patients with active pulmonary TB, 40 men and no women, mean age 38.1 ± 6.368 years. Group III included 40 patients with CAP caused by bacterial infection, 36 men and four women, mean age 49.425 ± 6.687 years. Informed consents were obtained from all the participants in this study.

Inclusion criteria
(1) Patients with active pulmonary TB fulfilled the following criteria:
   (a) Patients with clinical symptoms and signs of pulmonary TB.
   (b) Examination of sputum by Ziehl–Neelsen stain (three successive times) was positive for acid-fast bacilli.
(2) Patients with CAP fulfilled the following criteria [13]:
   (a) Acute illness characterized by symptoms and signs of lower respiratory infection.
   (b) New radiological shadowing for which there was no alternative explanation.
   (c) Acquired outside hospital.
   (d) Sputum Gram stain and culture showed that the causative organisms were bacteria. Sputum samples should fulfill the following criteria to maintain a sensitivity of 62% and a specificity of 85% to ensure that organisms present in the smear were not commensals: squamous epithelial cells (normally exfoliated from the oropharynx) less than 10 cells per low-power microscopic field, polymorphonuclear neutrophils 10–25 cells per low-power microscopic field, and there should be at least 10 organisms per oil immersion field [14].

Exclusion criteria
(1) Patients with lung infections other than pulmonary TB or CAP caused by bacterial infection.
(2) Bacterial CAP on top of viral infections of respiratory tract. This was diagnosed as pneumonia after flu manifestation although many studies found that serum level of PCT is not increased or even low in viral infections [15,16].
(3) Patients with negative smear pulmonary TB or extrapulmonary TB (diagnosed by history, clinical examination, and any investigation, available with the patients, proved this diagnosis).
(4) HIV patients.
(5) Patients with a history of other chronic respiratory diseases, for example chronic obstructive pulmonary disease, bronchial asthma, lung cancer, and IPF.
(6) Patients with chronic metabolic, endocrine, cardiovascular, or inflammatory diseases.
(7) Patients with CAP or active pulmonary TB under antimicrobial therapy.

The following were carried out for all participants:
Thorough assessment of history, full clinical examination, plain chest radiograph posteroanterior view, sputum examination for acid-fast bacilli by Ziehl–Neelsen stain three successive times for patients suspected of having tuberculosis. In patients with CAP, sputum examination by gram stain and culture was performed to detect causative microorganisms; also, blood culture was required in severe cases. Five milliliters of venous blood was withdrawn from each participant to measure the serum levels of CRP and PCT. Serum levels for CRP were measured using qualitative measurement of CRP (Biosystems S.A.Costa Brava 30, 08030 Barcelona–Spain on the basis of the latex agglutination method as follows:

(1) All reagents, controls, and serum samples were brought to room temperature.
(2) The CRP latex reagent was shaken gently before use. One drop of reagent was placed in the test circle. Using disposable pipettes, one drop of undiluted patient serum was placed on the same circle and both were mixed together with the paddle end of the pipette.
(3) Positive and negative controls were obtained with each series of test serum in the same way as in step 2.
(4) The slide was rotated back and forth for 2 min and the result was read under an indirect oblique light source [9].

Serum levels of PCT were measured using a commercially available ELISA kit supplied by ‘Raybiotech Inc.’ (3607 Parkway Lane, Suite 100, Norcross GA 30092, USA) according to the manufacturer’s instructions as follows:
(1) All reagents and samples were brought to room temperature (18–25 °C) before use.

(2) One hundred microliter of the standard and the sample were added to appropriate wells, covered, and incubated for 2.5 h at room temperature or overnight at 4°C with gentle shaking.

(3) The solution was discarded and washed four times with 1×wash solution by filling each well with wash buffer (300 μl) using a multichannel pipette or autowasher. Complete removal of the liquid at each step was performed and was important to achieve good performance. After the last wash, any remaining wash buffer was removed by aspirating or decanting. The plate was then inverted and blotted on clean paper towels.

(4) One hundred microliter of 1×prepared biotinylated antibody was added to each well and incubated for 1 h at room temperature with gentle shaking.

(5) The solution was discarded and the wash was repeated as in step 3.

(6) One hundred microliter of prepared Streptavidin solution was added to each well and incubated for 45 min at room temperature with gentle shaking.

(7) The solution was then discarded and the wash was repeated as in step 3.

(8) One hundred microliter of TMB One-Step Substrate Reagent was added to each well and incubated for 30 min at room temperature in the dark with gentle shaking.

(9) Fifty microliter of stop solution was added to each well and was read at 450 nm [9].

Statistical analysis
Mean values, SD, range, sensitivity, and specificity were determined in this study, and ANOVA test and Tukey’s test were used.

Results
The participants were older and there was a significant increase in serum CRP in group III compared with groups I and II, but there was no significant difference between groups I and II; also, there was a significant increase in serum PCT in group III compared with groups I and II, but there was significant increase in group II compared with group I. There was a significant positive correlation between serum PCT and serum CRP in groups II and III. The cut-off point of serum CRP between group II and group III was more than 24 mg/dl with a sensitivity of 100% and a specificity of 70%, but the cut-off point of serum PCT between both the groups was more than 530 pg/ml, with a sensitivity of 67% and a specificity of 97.5% (Tables 1–5 and Figs. 1–4).

| Group I | Age (years) | ANOVA |
|---------|-------------|-------|
| Range | Mean ± SD | F | P-value |
| 27.0–55.0 | 37.1 ± 10.8 | 29.406 | <0.001 |

| Group II | Age (years) | ANOVA |
|---------|-------------|-------|
| Range | Mean ± SD | F | P-value |
| 25.0–50.0 | 38.1 ± 6.3 | 6.687 | <0.001 |

| Group III | Age (years) | ANOVA |
|---------|-------------|-------|
| Range | Mean ± SD | F | P-value |
| 35.0–61.0 | 49.425 ± 6.68 | 6.687 | <0.001 |

| Group I and group II | Group I and group III | Group II and group III |
|---------------------|---------------------|---------------------|
| ANOVA | ANOVA | ANOVA |
| 22.101 | 13.22 | 13.22 |

| Group I and group II | Group I and group III | Group II and group III |
|---------------------|---------------------|---------------------|
| ANOVA | ANOVA | ANOVA |
| 0.915 | 0.048 | 0.048 |

| Group I | Serum procalcitonin (pg/ml) | ANOVA |
|---------|-----------------------------|-------|
| Range | Mean ± SD | F | P-value |
| 14.0–48.0 | 30.60 ± 10.8 | 13.22 | <0.001 |

| Group II | Serum procalcitonin (pg/ml) | ANOVA |
|---------|-----------------------------|-------|
| Range | Mean ± SD | F | P-value |
| 280.0–500.0 | 409.30 ± 14.6 | <0.001 |

| Group III | Serum procalcitonin (pg/ml) | ANOVA |
|---------|-----------------------------|-------|
| Range | Mean ± SD | F | P-value |
| 112.0–3016.0 | 711.85 ± 101.8 | 0.003 |

| Group I and group II | Group I and group III | Group II and group III |
|---------------------|---------------------|---------------------|
| ANOVA | ANOVA | ANOVA |
| 13.22 | 13.22 | 0.003 |

Discussion
Sahin and Yildiz [17] concluded that CRP is useful in the differential diagnosis of TB and pneumonia; the best serum CRP cut-off value was 9.4 mg/dl; also, a study by Yoon et al. [18] found that the mean values of serum CRP were significantly higher in CAP patients compared with pulmonary tuberculous (PTB) patients, with a sensitivity of 67.5% and a specificity of 85.1%. The CRP level is a nonspecific marker of acute-phase inflammation because it is subjected to the influence of other factors such as the general characteristics of
Differentiation between TB and CAP El-Shafey et al. 181

patients such as age and sex; thus, cut-off levels may be different from study to another. Ugajin et al. [19] found that the serum level of PCT was significantly lower in PTB patients compared with CAP patients, and concluded that serum PCT is not habitually increased in HIV-negative PTB patients and is a useful biomarker for differentiating between PTB and CAP. The poor response of serum PCT in PTB is because (a) secreted cytokine patterns are different between tuberculous infection and common bacterial infection and (b) serum PCT concentration increases slightly in intracellular infection, including that caused by mycoplasma and viruses. Kang et al. [3] studied 87 participants with suspected CAP in a community-based referral hospital. A clinical assessment was performed before treatment, and serum CRP and PCT were measured. The test results were compared with the final diagnosis. Of the 87 patients, 57 had bacterial CAP and 30 had pulmonary TB. The median CRP concentration was 14.58 mg/dl in patients with bacterial CAP and 5.27 mg/dl in those with pulmonary TB; also, the median PCT level was 0.514 pg/ml in patients with bacterial CAP and 0.029 pg/ml in those with pulmonary TB. They concluded that the concentrations of CRP and PCT were significantly higher in patients with bacterial CAP compared with pulmonary TB, and also found that PCT is superior in predicting the severity of bacterial CAP compared with CRP. Rasmussen et al. [1] concluded that in West African PTB patients, PCT levels were low but increased significantly with increasing severity of disease, and can predict the risk of mortality. As PCT synthesis and release are determined by the inflammatory cytokine cascade during systemic infection, the intensity depends on the number of organisms entering the systemic circulation; the number of organisms in PTB is probably lower than in bacterial pneumonia. The present study showed that there was a positive correlation between the serum PCT and serum CRP in patients with pulmonary TB and CAP. This was in agreement with the study of Rasmussen et al. [1] as they found positive correlations between both PCT and CRP. The current study showed, that the cut-off value of serum PCT of more than 530 pg/ml
had a sensitivity of 67% and a specificity of 97.5% between group II and group III. Nyamande and Laloo [20] concluded that PCT has a fairly high specificity for diagnosing CAP because of common bacterial pathogens (88%) as well as PTB (82%); however, the sensitivity is relatively low. They also concluded that PCT was more sensitive and specific than CRP in differentiating between both diseases. Ugain et al. [19] concluded that serum PCT has better diagnostic validity than CRP for differentiation between PTB and CAP, with a higher sensitivity and specificity. In this study, the low sensitivity and the high specificity of PCT as well as the high sensitivity and the low specificity of CRP in comparing between CAP and pulmonary TB prove that they are complementary tests for differentiation between both diseases. However, there are several limitations in this study; the sample size was not large, CAP bacterial causative pathogens were not clearly defined, and this work did not study the relation between PCT and CRP concentrations and the severity of CAP or the effect of antimicrobial therapy. Therefore, further studies should be carried out taking into consideration the above-mentioned points.

Acknowledgements

Conflicts of interest
None declared.

References
1. Rasmussen TA, Sogaard SO, Camara C. Serum procalcitonin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2011; 15:2.
2. Naderi M, Hashemi M, Kouhpayeh H. The status of serum procalcitonin in pulmonary tuberculosis and non tuberculosis pulmonary disease. Research Center for Infectious diseases and Tropical Medicine, Department of Clinical Biochemistry, Cellular and Molecular Research Center School of Medicine. J Pak Med Assoc 2009; 59:647–648.
3. Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009; 24:337–342.
4. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121:219-225.
5. Baqadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139:1410-1418.
6. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21:938-943.
7. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28:68–73.
8. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001; 84:332–336.
9. Kofod E, Andersen O, Kronbong G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007; 11:R38.
10. Farr BM, Kaiser DL, Harrison BD, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44:1031–1035.
11. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C, Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405–1433.
12. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl 4): IV1–IV64.
13. Caroline MP, Micheal RL. Community acquired pneumonia: assessment and treatment. Clinical Medicine 2012; 12:283–286.
14. Fishman AP, Elias JA, Fishman JA, et al. Fishman’s manual of pulmonary diseases and disorders. 3rd ed. USA: McGraw-Hill Companies Inc.; 2002. Fishman JA, Approach to the patient with pulmonary infection. 661-699.
15. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 (Suppl 4): S346–S350.
16. Delévaux I, André M, Colombier M, Albuisson E, Meyheuc F, Bègue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003; 62:337–340.
17. Sahin F, Yildiz P. Distinctive biochemical changes in pulmonary tuberculosis and pneumonia. Arch Med Sci 2013; 9:656–661.
18. Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. Ann Lab Med 2013; 33:105–110.
19. Ugain M, Miwa S, Shirai M, Ohba H, Eifuku T, Nakamura H, et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011; 37:371–375.
20. Nyamande K, Laloo PG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10:510–515.